Key facts
- Turn Therapeutics (NAS: TTRX)’s last known valuation is $162.5M (May 2024).
- It has raised $100.5M; the latest was General Corporate Purpose ($25.0M) in Mar 2026.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Turn Therapeutics (NAS: TTRX)
- ·The full record, as it builds
Funding rounds
No funding rounds for Turn Therapeutics (NAS: TTRX) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Turn Therapeutics (NAS: TTRX)
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
- Sector
- Healthcare
- HQ
- Westlake Village, CA, United States
- Founded
- 2015
- Employees
- 2
- Website
- turntherapeutics.com/
- Ownership
- Publicly Held
Turn Therapeutics (NAS: TTRX) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Turn Therapeutics (NAS: TTRX) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Turn Therapeutics (NAS: TTRX) in its N-PORT filings yet. We sweep new filings monthly.